C3

Across TCGA pan-cancer cohorts, C3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated C3 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated C3 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where C3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.329	0.816	.001	33	view →
LSCC	DFS	Median	II,III,IV	0.836	1.000	.005	15	view →
CCRCC	DFS	Median	All	0.908	0.711	.009	13	view →
PDAC	OS	Median	III,IV	0.294	0.572	.013	10	view →
UCEC	DFS	Tertile	III,IV	0.367	1.000	.020	8	view →
COAD	DFS	Median	IV	0.565	1.000	.028	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

C3–LUAD (OS)

Open the LUAD breakdown →